Evolving Immunotherapy Approaches for Renal Cell Carcinoma

Susanna A. Curtis, Justine V. Cohen, Harriet M. Kluger

Research output: Contribution to journalReview articlepeer-review

22 Scopus citations


Metastatic renal cell carcinoma (mRCC) continues to be associated with high rates of morbidity and mortality. Renal cell carcinoma (RCC) is typically resistant to cytotoxic chemotherapy, and while targeted therapies have activity and prolong progression-free and overall survival, responses are usually not durable. Modulating the immune system with cytokine therapy, vaccine therapy, cell therapy, and checkpoint inhibitors offers hope of prolonged survival. Standard and emerging immune therapy approaches and combinations of immune therapies and other modalities are reviewed.

Original languageEnglish (US)
Article number57
JournalCurrent oncology reports
Issue number9
StatePublished - Sep 1 2016
Externally publishedYes


  • Adoptive cell therapy
  • Cytokines
  • Immune checkpoint inhibitors
  • Immunotherapy
  • Renal cell carcinoma
  • Vaccine therapy

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Evolving Immunotherapy Approaches for Renal Cell Carcinoma'. Together they form a unique fingerprint.

Cite this